Resveratrol for Exudative Age-Related Macular Degeneration

Influence of Resveratrol and Resvega Versus Placebo on Incidence of Bilateralisation of Exudative AMD: a Double Masked Prospective Study.

Status

Terminated

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02625376

Acronym

AGED

Enrollment

Registered

2015-12-09

Start date

2015-08-06

Completion date

2016-11-09

Last updated

2020-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Age-related Macular Degeneration, AMD, Choroidal Neovascularisation

Brief summary

This is an interventional, prospective, randomized, comparative monocentric study aiming to evaluate the safety and efficacy of Resveratrol to reduce the progression of exudative Age-Related Macular Degeneration.

Detailed description

Interventional, prospective, randomized, comparative monocentric study aiming to evaluate the safety and efficacy of Resveratrol to reduce the progression of exudative Age-Related Macular Degeneration. Comparison of incidence of choroidal neaovascularization between each study group will be performed.

Interventions

DIETARY_SUPPLEMENTResvega

Dietary supplementation with Resvega BD

DIETARY_SUPPLEMENTTrans-Resveratrol

Dietary supplementation with resveratrol 250 mg BD

DIETARY_SUPPLEMENTplacebo

Dietary supplementation with a placebo BD

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

55 Years to No maximum

Healthy volunteers

Inclusion criteria

* Men or women aged 55 or more with unilateral exudative AMD * Visual acuity less or equal to 20/25 in the most affected eye

Exclusion criteria

* Allergy to an investigational product * atrophic Age-Related Macular Degeneration or age related maculopathy * significant media opacities * Other retinal pathology (diabetic retinopathy, high myopia, retinal dystrophy) * Recent Cataract surgery * Previous history of vitrectomy * Acute or chronic severe organ failure * Present participation in other clinical research study

Design outcomes

Primary

Measure	Time frame	Description
Comparaison of incidence of choroidal neovascularization between resveratrol group and placebo group at 24 months	24 months	What is the influence of the daily intake of 500 mg of resveratrol on the incidence of neovascularization of the second eye?

Secondary

Measure	Time frame	Description
Comparaison of incidence of choroidal neovascularization between Resvega group and placebo group at 24 months	24 months	What is the influence of the daily intake resvega on the incidence of neovascularization of the second eye?

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026